SCHEMBL818858

SCHEMBL818858

CCCc1[c]c(C)ccc1

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.30
GABRB2 P47870 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL820841 0.87 KCNH2 (0.35)
SCHEMBL185493 0.85 KCNH2 (0.33)
SCHEMBL8671436 0.84 KCNH2 (0.46)
SCHEMBL1777251 0.84 KCNH2 (0.46)
SCHEMBL177368 0.81
SCHEMBL8466418 0.80
SCHEMBL5264255 0.80 TDP1 (0.34)
SCHEMBL820116 0.79 GABRA1 (0.31) GABRA1GABRB2
SCHEMBL820424 0.77 KCNH2 (0.38)
SCHEMBL16439955 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3752494-A1 REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METATHESIS CATALYSTS UMICORE AG & Co. KG (DE) 2020-12-23 EP claimed
WO-2019158485-A1 REACTIONS OF OLEFIN DERIVATIVES IN THE PRESENCE OF METATHESIS CATALYSTS UMICORE AG & CO. KG (DE) 2019-08-22 WO claimed
EP-3503999-A1 SYNTHESIS AND CHARACTERIZATION OF METATHESIS CATALYSTS UMICORE AG & CO. KG (DE) 2019-07-03 EP claimed
EP-3496855-A1 METATHESIS CATALYSTS UMICORE AG & CO. KG (DE) 2019-06-19 EP claimed
WO-2018038928-A1 SYNTHESIS AND CHARACTERIZATION OF METATHESIS CATALYSTS MATERIA, INC. (US) 2018-03-01 WO claimed
WO-2018034931-A1 METATHESIS CATALYSTS MATERIA, INC. (US) 2018-02-22 WO claimed
US-8426429-B2 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) JANSSSEN PHARMACEUTICA N.V. (BE) 2013-04-23 US claimed
EP-1776350-B1 NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE ) JANSSEN PHARMACEUTICA NV (BE) 2013-01-23 EP claimed
CN-101035770-B 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA NV 2011-02-23 CN claimed
CN-101035770-A Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA NV (BE) 2007-09-12 CN claimed
EP-1776350-A1 NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE ) JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-25 EP claimed
US-20060079686-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) JANSSEN PHARMACEUTICA NV (BE) 2006-04-13 US claimed
WO-2006017844-A1 NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-02-16 WO claimed
EP-3583211-B1 METHOD FOR THE SYNTHESIS OF DNA CONJUGATES BY MICELLAR CATALYSIS UNIV DORTMUND TECH (DE) 2024-04-10 EP disclosed
EP-3986995-A1 1-ALKOXYETHYL-4-ISOBUTYL-BENZENE AS AROMA INGREDIENTS BASF SE (DE) 2022-04-27 EP disclosed
US-20220002712-A1 METHOD FOR THE SYNTHESIS OF DNA CONJUGATES BY MICELLAR CATALYSIS TECHNISCHE UNIVERSITÄT DORTMUND (DE) 2022-01-06 US disclosed
EP-0414511-A1 Thiadiazole derivatives and herbicide compositions containing the same Tosoh Corporation (JP) 1991-02-27 EP disclosed
US-4427814-A DIPHOSPHONITE STABILIZER MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1984-01-24 US disclosed
US-4169106-A Antiarrhythmic N,N'-bis(phenylcarbamoylalkyl)amidines COOPER LABORATORIES, INC. (US) 1979-09-25 US disclosed
US-4069223-A ANTIDIARRHEA G. D. SEARLE & CO. (US) 1978-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079686-A1 Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) BACE2, BACE1, APP GABRA1 876/4885GABRB2 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.